Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tourmaline Bio

16.76
+0.75004.68%
Post-market: 16.760.00000.00%17:18 EDT
Volume:439.15K
Turnover:7.32M
Market Cap:430.49M
PE:-5.80
High:17.20
Open:15.84
Low:15.49
Close:16.01
Loading ...

Company Profile

Company Name:
Tourmaline Bio
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
74
Office Location:
27 West 24th Street,Suite 702,New York,New York,United States
Zip Code:
10010
Fax:
- -
Introduction:
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline also comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). Tourmaline Bio, Inc. was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was incorporated in 2002 and is based in New York, New York.

Directors

Name
Position
Francois Nader
Chairman of the Board
Scott Requadt
President, Chief Executive Officer and Director
Suzanne T. Ildstad
Chief Scientific Officer and Director
Gaurav D. Shah
Director
Geoff MacKay
Director
Mark D. McDade
Director
Nicholas G. Galakatos
Director
Sandip Agarwala
Director
Sapna Srivastava
Director

Shareholders

Name
Position
Scott Requadt
President, Chief Executive Officer and Director
Mary Kay Fenton
Chief Financial Officer
Michael Zdanowski
Chief Technology Officer
Nancy Krieger
Chief Medical Officer
Suzanne T. Ildstad
Chief Scientific Officer and Director